Background {#Sec1}
==========

Worldwide, cervical cancer is the fourth leading cause of death among women \[[@CR1]\]. In 2018, 570,000 new cases of cervical cancer were diagnosed worldwide; the vast majority, around 90%, occurred in low income countries \[[@CR1]\]. Screening program based on cytology in developed countries has been proven successful, resulting in a rapid decrease in the incidence and mortality rates of cervical cancer \[[@CR2]\]. In developing countries, the incidence of cervical cancer remains high. The main factor contributing to this situation is the difficulty to establish and maintain quality prevention programs based on cytology (Papanicolaou). This could explain partially the low screening coverage \[[@CR3]\]. To improve the screening in developing countries, other screening methods including the high-risk human papilloma virus (HR-HPV) DNA detection were introduced \[[@CR4]\]. The HPV tests are based on the identification of persistent infections by HR-HPV that are essential for the development of precancerous cervical lesions and cervical cancer \[[@CR4], [@CR5]\]. The use of this method as a screening test for cervical high-grade intraepithelial neoplasia (CIN 2 +), turned out to be highly effective, in term of sensitivity, and could be an alternative in cervical cancer primary screening \[[@CR6]\]. Another advantage is that it allows self-sampling, an interesting procedure in rural areas, as it removed barriers related to clinic visit apprehension and the discomfort of a cytological test \[[@CR7]\] .On the other hand, visual inspection with acetic acid (VIA) is also an effective test for the prevention of cervical cancer, allowing detection of early cervical epithelia changes after the acetic acid (3--5%) application for the prevention of cervical cancer in low-resource settings \[[@CR8], [@CR9]\]. However, its clinical performance is observer dependent \[[@CR9]\].

The situation in Bolivia is alarming regarding the incidence and mortality rates of uterine cervix cancer, with the highest incidence in America (38 per 100,000 women) and a mortality rate of 19 per 100,000 women (rates standardized by age) \[[@CR10]\]. The main reasons to inadequate prevention of cervical cancer in Bolivia are the low screening coverage of the Papanicolaou smear cytology test (Pap smear), the lack of follow up of the positive cases, the poor information given on cervical cancer prevention, the deficient training of the health staff, the low credibility in the public health system and finally economic, geographic and sociocultural barriers reducing the access of the Bolivian to health care centers \[[@CR11], [@CR12]\].

Screening, offered by the first level of care, responsible for prevention, is available free of charge, for sexually active women until 64 years old \[[@CR13]\]. Nevertheless, Pap smear coverage, from 2005 to 2016, didn't exceed 16.6% and coverage of VIA in 2015 and 2016 didn't exceed 19% \[[@CR14]\]. The health personnel estimated that 50 to 80% of PAP screened women were lost to follow-up, mainly because of delays in result delivery \[[@CR11]\].

To improve this situation, our group has recently evaluated the acceptability of introducing an HR-HPV test on self-collected samples with cheap and simple devices \[[@CR12], [@CR15]\]. Indeed, we have previously shown the analytical performance of the HR-HPV detection on samples self-collected with a cotton swab, dried before transport on glass slide \[[@CR15]\]. Our HR-HPV detection method involves two PCR based techniques: a BSGP5+/6+ PCR--EIA method and a pU1ML-2R PCR. This strategy was recently described and analytically validated in comparison to the commercially available Hybrid Capture II method \[[@CR16]\].

The purpose of this study is to determine the clinical effectiveness of our HR-HPV DNA detection strategy on self-collected samples to detect high grade intraepithelial lesions and cervical cancers, comparing it to Pap smear analysis and VIA, in order to identify the best combination to screen Bolivian women or to sort women at risk.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Between January 2016 and April 2018, a cross-sectional study was carried out in Cochabamba (Bolivia) within the framework of the inter-institutional cooperation agreement between the "Universidad Mayor de San Simon" and the Public health service of Cochabamba (SEDES). Through these two institutions, a cervical pathology clinic was equipped at Hospital Cochabamba, where the present study was carried out. The staff consisted of a nurse assistant and a gynecologist trained in colposcopy and VIA during the two previous years.

The Bio-ethical committee of the "Universidad Mayor de San Simon" approved the study protocol (December 12, 2015). A total of 469 women were included in this study, divided in two groups.

The first group (phase 1) included 362 women that underwent three screening tests: HR-HPV DNA detection, Pap smear, and VIA, performed consecutively at the consultation. The women in this group assisted spontaneously or were referred from general medicine clinics to the cervical pathology clinic of Cochabamba hospital due to their gynecological symptoms. This phase 1 study was named "the screening group". The second group (phase 2) included 107 women referred with a positive HR -HPV DNA detection test, these women were identified in cervical cancer prevention campaigns conducted in different geographical areas of the city of Cochabamba (urban and rural). They underwent additional Pap smear and VIA tests, and this study group was named "the referred group". All women (phase 1 and 2) were examined by colposcopy after the three (screening group) or two (referred group) screening tests. Biopsy was performed when necessary, according to the colposcopy observation results. (Fig. [1](#Fig1){ref-type="fig"}). In addition, data on the characteristics of the population were collected from the gynecological clinical history and from our own project database. Fig. 1Colposcopic and biopsy results in the screening and referred groups. The number of study participants is given in bold

The signed informed consent and an adequate colposcopy were indispensable requisites for the patient inclusion in this study. Pregnant women and women with a hysterectomy or under 25 years of age or older than 64 years were excluded from this study according to nationals and international recommendations. In the referred group an additional inclusion factor was applied as all participants were required to have a positive HR-HPV test. In contrast, we applied an additional exclusion factor for the screening group, being that none of patients should have had previous results, positive or negative, of a HR-HPV test, VIA test or cytology analysis. All inclusion and exclusion factors were applied before the gynecological evaluation, except for the "adequate colposcopy" inclusion factor that was applied during the colposcopy evaluation.

HR-HPV detection test {#Sec4}
---------------------

A kit, previously described and analytically validated, was provided to the women at the clinic consultation (or, for the referred group women, eventually at home or on the marked during promotional campaigns) to perform vaginal self-sampling in order to analyze their samples in a HR-HPV DNA detection assay \[[@CR15]\]. The kit contained a pair of sterile gloves, a cotton swab and a sterile glass slide fixed in a paper box on which the personal data of the patient can be written \[[@CR15]\]. The protocol for the use of the self-sampling device was explained in detail to the woman by a trained health staff for both groups (screening and referred group) as previously described \[[@CR15]\]. The extracted DNA quality was first evaluated by a ß-globin PCR. Only samples with ß-globin PCR positive results were further processed. Two consensus PCR (BSGP5+/6+ and PU1ML-2R) allowed for HR-HPV detection \[[@CR16]\]. The BSGP5+/6+ primers are an improvement of the original set of primers GP5+/6+ targeting the HPV L1 sequences \[[@CR16]\] An immune-enzymatic assay (EIA) was performed subsequently on BSGP5+/6+ PCR samples to identify specifically HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 using digoxigenin-labelled probes \[[@CR16]\]. The pU1ML-2R PCR targets the E6/E7 regions of at least 6 HR-HPV types: 16, 18, 31, 33, 52 and 58. A sample was considered positive for HR-HPV when any of these two tests (PU1ML-2R PCR and BSGP5+/6+ PCR/EIA) yielded a positive result \[[@CR16]\].

Cytological analysis {#Sec5}
--------------------

Samples for conventional cytology analysis (Pap smear) were taken from the cervical transformation zone by the gynecologist. The smear was spread on a glass slide and stained, according to the Papanicolaou method \[[@CR17]\]. The analyses were performed at the Viedma Hospital cytology laboratory and in private cytology laboratories, as requested by the patients. The quality control of public and private cytopathology laboratories is carried out annually under the supervision of the Ministry of Health of Bolivia through the "Normative Laboratory Documents" \[[@CR18]\]. A cytology test was considered positive in case of ASCUS or more severe lesion.

Visual inspection under acetic acid {#Sec6}
-----------------------------------

The Visual Inspection under Acetic Acid (VIA) was made with white wine vinegar with an acetic acid concentration of 5%, one minute after the application. The solution was changed every 2 weeks. The cervix was observed under a white LED light and the test was considered positive when the presence of aceto-white lesions was found in the squamo-columnar junction or near to an opening in the center of the ectocervix known as Os. Otherwise it was considered negative \[[@CR19]\]. VIA results were recorded in a notebook by a nurse before colposcopy analysis.

Colposcopy {#Sec7}
----------

Colposcopy was a separate independent examination, performed after the three screening tests, on the same day (VIA and colposcopy were done by the same examiner). The decision to take a biopsy was based on the results of the colposcopy, using the classification of the IFCPC ("Adequate/inadequate" "normal ", "minor lesion or colposcopy grade I", major lesion or colposcopy grade II"," and "suspicious for invasion") \[[@CR20]\]. A biopsy was taken when the results of the colposcopy was equal or greater than a colposcopy grade I (minor lesion), The diagnosis of a cervix without anomalies was provided by the colposcopic impression, in these cases the biopsy was no taken, according to Bolivian guidelines \[[@CR21]\].

Biopsy analysis {#Sec8}
---------------

Biopsies were processed in the reference laboratory of Pathology of the Bolivian-Japanese gastroenterological hospital. Histological classification (CIN) of epithelial lesions of the cervix were used according to the description made by Richart \[[@CR22]\]. Samples of 29 biopsies were chosen by simple random sampling out of 101 biopsies between low-grade (CIN1), high-grade intraepithelial lesions (CIN2, CIN3) and invasive cancer were sent for quality control to the laboratory of Prof. Philippe Delvenne (Department of Pathological Anatomy, B23 CHU Sart Tilman - 4000 Liège, Belgium) for rereading.

A CIN 2 severity grade was determined as the "cut off" in the biopsy result in this study, considering that people whose lesion were exceeding this cut off had a positive gold standard result while those having a lower severity grade results were considered as negative in this gold standard assay.

Statistics {#Sec9}
----------

Statistical analyses were performed independently on available results using cross tables to determine the sensitivity, specificity and predictive values of each test. Number of true positives, true negative, false positives and false negative cases were calculated considering the biopsy analysis result (obtained in Bolivia) of CIN2 as a cut off to detect CIN2+ and cervical cancer (gold standard for positive cases) and considering negative colposcopy result or normal or CIN1 biopsy analysis result as negative cases. The confidence limits for each proportion were calculated with OpenEpi software (Normal Approx.)**.**

Results {#Sec10}
=======

Characteristics of the study population {#Sec11}
---------------------------------------

Characteristics of the women, aged between 25 and 64 years, participating either to the screening group (*n* = 362) or the referred group (*n* = 107) are presented in Table [1](#Tab1){ref-type="table"}. Table 1Characteristics of the population found in the two groupsScreening (362) NReferred (107) NScreening and Referred (469) NData(n)meanNo data(n)Data(n)meanNo data(n)Data(n)meanNo data(n)Age36240010736.2046938.10Menarche33513276812.93940312.9566First sexual intercourse33518.4276817.53940317.9566Number of sexual partners334228682.2394022.167Pregnancies320342672.9403872.9582

Sensitivity, specificity and predictive values of HR- HPV, pap smear and VIA to detect CIN 2+ or worse lesions in a primary screened population {#Sec12}
-----------------------------------------------------------------------------------------------------------------------------------------------

In the first phase 1 of our study we compared three primary screening tests to detect high-grade intraepithelial lesions and cervical cancer (CIN2+ or worse) in our study population. This phase 1 study, was performed on 362 women, named "the screening group", that underwent, consecutively, HR-HPV DNA detection by self-sampling, Pap smear and VIA, before colposcopy. A biopsy was performed when necessary, according to the colposcopy observation results. In this screened group, 72 biopsies were taken, out of which16 had high-grade intraepithelial lesions (CIN2+) and 8 had invasive cancer. The rest of the biopsies had a result lower than CIN2. The sensitivity, specificity and predictive values of the three screening tests to detect CIN2+ lesions or worse, based on the biopsy results (gold standard) were determined through the analysis of the results of 362 patients. The sensitivity and specificity were respectively: 44 and 93% for the PAP, 100 and 86% for the VIA and 76 and 78% for the HR-HPV test. The positive and negative predictive values were, respectively, 30 and 96% for PAP, 35 and 100% for VIA, 18 and 98% for HR-HPV test (Table [2](#Tab2){ref-type="table"}). Table 2Screening group (CIN 2+ or worse)**Cytology**^a^NNegative referencetestPositive reference testPPV%NPV%95% ICPositive261883013--48Negative257247109693--98Total283Sensitivity44%21--67Specificity93%90--96**VIA**Negative referencetestPositive reference testPPV%NPV%95% ICPositive6844243524--46Negative2942940100Total362Sensitivity100%Specificity86%83--90**HPV**^b^NNegative referencetestPositive reference testPPV%NPV%95% ICPositive8771161810--26Negative25925459896--99total346Sensitivity76%57--94Specificity78%73--82^a^cytology lost samples = 79^b^HPV lost samples = 16

Sensitivity, specificity and predictive values of pap smear and VIA to detect CIN 2+ or worse lesion in a HR-HPV DNA positive population {#Sec13}
----------------------------------------------------------------------------------------------------------------------------------------

In the group of referred women, 29 biopsies were obtained, from which 11 corresponded to high-grade intraepithelial lesions (CIN2+) and 4 to invasive cancers, the rest of the biopsies had a result lower than CIN2. The sensitivity, specificity and positive values of the two screening tests to detect high-grade intraepithelial lesions and cervical cancer (CIN2+ or worse) were determined through the analysis of the results of 107 patients. The sensitivity and specificity were respectively: 81 and 88% for the PAP, 100 and 85% for the VIA and the positive and negative predictive values were 64 and 95% for the PAP, 53 and 100% for the VIA, respectively (Table [3](#Tab3){ref-type="table"}). Table 3Referred group CIN2+ or worseCytology^a^NNegative referencetestPositive referencetestPPV%NPV%95% ICPositive14596439--89Negative424029589--100Total56Sensitivity81%59--100Specificity88%79--98VIANNegative referencetestPositive referencetestPPV%NPV%95% ICPositive2813155335--72Negative79790100Total107Sensitivity100%Specificity85%78--92^a^lost samples: 51

Quality control of the gold standard procedure {#Sec14}
----------------------------------------------

The Bolivian anatomo-pathology analyses were assessed by rereading in a Belgian laboratory, 29 biopsies out of 101 biopsies, chosen randomly by a technician from the Laboratory of Virology at the Universidad Mayor de San Simón, Cochabamba, Bolivia in the case of CIN1 lesion biopsies or according to availabilities for the CIN2+ lesion biopsies. The comparison of biopsies results between the Bolivian anatomo-pathology reference laboratory and the CHU Liège pathology laboratory (Belgium) gave a concordance of 84% for the CIN2 + lesions and an agreement of 70% for the lesions CIN 1 lesions (Additional file [1](#MOESM1){ref-type="media"}).

Screening samples lost in the study population {#Sec15}
----------------------------------------------

We analyzed sample lost in the two study group. There were losses in the results of the HR-HPV test (4% in the screened group) but also mainly in the cytology analyses (22 and 48% in the screened and referred group, respectively). As VIA was performed immediately, on the place, all the results were available for this test (Table [4](#Tab4){ref-type="table"}). Table 4Lost samples in the study populationScreening groupStudy population N (%)Lost samples N (%)Final Study population N (%)Cytology362 (100)79 (22)283 (78)VIA362 (100)0362 (100)HPV362/100)16 (4)346 (96)**Referred group** Cytology107 (100)51 (48)56 (52) VIA107 (100)0107 (100)

Discussion {#Sec16}
==========

Bolivia has one of the highest levels of incidence and mortality of cervical cancer in America \[[@CR10]\]. This study was conducted to compare the effectiveness to detect CIN 2+ or worse lesions using either one of the two primary screening tests usually performed in Bolivia, the Pap cytological test and the visual inspection with acetic acid test, or the HR-HPV DNA test, performed here by a new PCR/EIA based strategy on self-collected samples. Indeed, we previously reported that the PCR/EIA strategy had a very good performance compared to the hybrid capture II test (kappa value of 0.82) \[[@CR16]\].

The correct performance of a screening test can be assessed by analyzing several characteristics: the diagnostic accuracy to discriminate between a target condition and a good health, measured by the sensitivity and specificity values, and, on the other hand, the positive and negative predictive values to evaluate the performance of a screening test in a population \[[@CR23]\].

The clinic sensitivity and specificity of our low cost self-sample HR-HPV test to detect CIN 2+ or worse lesions in the screened group were 76 and 78%, respectively, giving higher detection values than cytology but lower to the VIA. Despite its moderate sensitivity to detect a CIN2+ lesion or worse, its negative predictive value was high as expected (98%). It is worth noting that the HR-HPV test was robust, giving results with no inter-observer variation \[[@CR16]\]. The main advantage of this screening method is that it allows reaching women from rural areas or women rejecting the gynecological revision \[[@CR7], [@CR12], [@CR15], [@CR24]\]. As the VIA test, the HPV test had a low positive predictive value (18%) requesting an additional triage methodology, as previously reported \[[@CR25]--[@CR29]\].

The cytology in the screened group showed a low sensitivity (21--67%) and a specificity of 92%, to detect CIN2 + lesion or worse, giving the lowest performance amongst the evaluated tests. Similar results were obtained in an extensive study conducted in European and North American countries, reporting a low sensitivity (53%) and a high specificity (96%) of the PAP staining to detect CIN2 + lesions \[[@CR6]\]. The poor performance of the cytology in developing countries and the poor follow-up of positive cases led to the introduction of alternative screening approaches, based on VIA and/or on HR-HPV detection tests.

The screening of patients with VIA allowed to detect high-grade intraepithelial lesions (CIN2 + or worse) with 100% sensitivity and 86% specificity. Other studies reported similar results with 79% sensitivity and 89% specificity in Africa and India \[[@CR30]\], 83% sensitivity and 89% specificity in Mongolia \[[@CR31]\], 73% sensitivity and 80% specificity in Kenya \[[@CR32]\]. Nevertheless other studies obtained contrasting results with a low sensitivity and high specificity in Rwanda (41% Sensitivity and 96% specificity), \[[@CR33]\] or a moderate sensitivity with high specificity in Thailand (67.9% sensitivity and 100% specificity) \[[@CR34]\]. This considerable variation between studies on the accuracy of VIA in the detection of high-grade lesions (CIN2 +) is possibly attributable to inter-observer variation, skill levels, light used and acetic acid concentration \[[@CR35]\] .In our study, as there was only one observer previously trained in visual screening and colposcopy (2 years) that could explain the 100% sensitivity.

VIA generally gave a large number of false positive, leading to low positive predictive value (34%) \[[@CR36]\] .This indicates the need of a triage method to avoid a burden to public health-care service by a large number of required confirmatory colposcopies under gynecological review. This is especially important in Bolivia as the public health system has great limitations for the follow-up and treatment of patients \[[@CR11]\].

We also assessed the performance of the VIA and the Pap smear test as triage method for HR-HPV positive women (referred women). Although the number of samples with CIN2 + lesions was small, because losses of samples in cytology (around 50%), the results suggested that both tests give better positive predicted value in triage compared to their use in screening.

Bolivia is one of the poorest countries in South America and its public health system had difficulties in the monitoring and treatment of pre-malignant lesions of the cervix detected by cytology. This is partly due to the fact that 38% of the cytology results were lost \[[@CR37]\], as observed in our study, with a loss of 22 and 48% of the cytological results in the screening group and referred group respectively. Furthermore, cytological results were delivered only after a minimal 45 days. Taking this into account but also the low sensitivity found for cytological analyses, many women were not being properly diagnosed with CIN2+ or cervical cancer (67% of the screening group and 40% of the referred group) when diagnosis was only based on cytology. On the other hand only some health services have colposcopes and few personnel are trained to treat pre malignant lesions \[[@CR11], [@CR13]\]. In that context, the strategy of a "unique visit" to "see and treat" in which treatment by cryotherapy or cold coagulation is eventually provided to women with positive detection results in the HR-HPV detection test and VIA analysis, is particularly adapted for low-income countries \[[@CR38], [@CR39]\]. This strategy could be the most suitable for Bolivia to reduce the incidence and mortality of cervical cancer. Furthermore, HPV based screening could allow extension of the cervical screening interval beyond 5 years, potentially reducing the public health burden, as recently proposed \[[@CR40]\].

A limiting factor in our study was that a confirmatory biopsy was not performed on women with a normal colposcopy result. The final result on the condition of their cervix was based only on colposcopy impression (that could have led to the higher specificity of the VIA). This limitation was due to ethical and technical reasons, as our intervention followed the official guidelines from the Bolivian Ministry of Health \[[@CR21]\]. This could have also reduced the specificity of the cytology and HR-HPV tests (by increasing the amount of false positives). Indeed, there could be microscopic CIN2 + lesions not visible to the human eye or by colposcopy examination, but that still could be detected by cytology or the HR-HPV test, which would have led to false categorization, as false positives. Indeed colposcopy is not sufficiently precise, although useful in estimating lesion grade \[[@CR41]--[@CR44]\]. Nevertheless, most studies, like us, determine the final negative status of the cervix for CIN 2 through colposcopy when lesion is not evident, and use this result as a true negative clinical condition \[[@CR32], [@CR45]--[@CR47]\].

Conclusions {#Sec17}
===========

Our results suggest that the VIA and our low cost HR-HPV DNA PCR detection assay have better sensitivity to detect cervical cancer and its true precursor lesions, compared to standard Bolivian PAP smear test. Among all evaluated test the cytology analysis showed the lowest performance to detect CIN 2+ lesion or worse, even at the lowest cytological cut-off (ASCUS).

Since our self-sampled HR-HPV detection test (HPV screening) could overcome sociocultural barriers and to increase screening coverage \[[@CR12]\], an also showed an acceptable sensitivity and negative predictive value, we propose that it could be combined with a triage method, like the VIA (i.e. in a see and treat strategy), considering the complementary high specificity and the possibility to give immediate results with the VIA, to eventually immediately allow for CIN2+ lesion treatment by cryotherapy. The cytology analysis, Pap smear test, on the other hand, is not the most appropriate screening test for Bolivia due to its poor performance to detect CIN2 + or worse, its long delay for delivering result and its large number of lost samples.

Finally, to improve the screening coverage, it is also essential to better sensitize the population through the education and facilitate access to screening results. Furthermore, it is essential to establish monitoring of the flow of exams, to identify the cause of delaying results and to develop new strategies that could insure delivery of the results in time but also that could improve the patient adherence to their gynecological health follow-up.
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**Additional file 1.** Bolivian anatomo-pathology analyses, by rereading 29 biopsies out of 101 biopsies chosen at random in a Belgian laboratory.
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